Long-duration, weekly treatment with gemcitabine plus vinorelbine for non-small cell lung cancer: A multicenter phase II study

Lung Cancer

Volumn 51, Issue 3, 2006, Pages 347-355

  Westeel, V ^a   Breton, J L ^b   Braun, D ^c   Quoix, E ^d   Milleron, B ^e   Debieuvre, D ^f   Jacoulet, P ^a   Germa, C ^g   Kayitalire, L ^g   Depierre, A ^a  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^b HÔPITAL DU BOCAGE   (France)

^c Centre Hospitalier General Maillot   (France)

^d UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^e HÔPITAL TENON   (France)

^f Centre Hospitalier Paul Morel   (France)

^g Lilly France   (France)

Author keywords

Gemcitabine; Long duration treatment; Non small cell lung cancer; Vinorelbine

Indexed keywords

GEMCITABINE; NAVELBINE;

ACUTE RESPIRATORY FAILURE; ADULT; AGED; ALLERGY; ALOPECIA; ANEMIA; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HISTOPATHOLOGY; HUMAN; HYPERTENSION; INFECTION; LIVER TOXICITY; LONG TERM CARE; LUNG EDEMA; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MALE; METABOLIC DISORDER; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL RATE; TREATMENT OUTCOME; VINBLASTINE;

EID: 33144488975     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2005.10.011     Document Type: Article

References (41)

1. R.C. Lilenbaum, P. Langenberg, and K. Dickersin Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: a meta-analysis of response, toxicity, and survival Cancer 82 1998 116 126
2. A. Depierre, G. Freyer, and J. Jassem Oral vinorelbine: feasibility and safety profile Ann Oncol 12 2001 1677 1681
3. J. Crawford Update: vinorelbine (navelbine) in non-small cell lung cancer Semin Oncol 23 2 Suppl 5 1996 2 7
4. C. Manegold, P. Zatloukal, and K. Krejcy Gemcitabine in non-small cell lung cancer (NSCLC) Invest New Drugs 18 2000 29 42
5. G. Krajnik, W. Wein, and R. Greil Vinorelbine/gemcitabine in advanced non-small-cell lung cancer (NSCLC): a phase I trial Eur J Cancer 34 1998 1977 1980
6. V. Lorusso, F. Carpagnano, and G. Frasci Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small-cell lung cancer J Clin Oncol 18 2000 405 411
7. J.P. Delord, E. Raymond, and M. Chaouche A dose-finding study of gemcitabine and vinorelbine in advanced previously treated malignancies Ann Oncol 11 2000 73 79
8. L. Norton Conceptual basis for advances in the systemic drug therapy of breast cancer Semin Oncol 24 4 Suppl 11 1997 S11 S12
9. M.J. Piccart, L. Biganzoli, and A. Di Leo The impact of chemotherapy dose density and dose intensity on breast cancer outcome: what have we learned? Eur J Cancer 36 Suppl 1 2000 S4 S10
10. H. Anderson, B. Lund, and F. Bach Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study J Clin Oncol 12 1994 1821 1826
11. R.P. Abratt, W.R. Bezwoda, and G. Falkson Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study J Clin Oncol 12 1994 1535 1540
12. U. Gatzemeier, F.A. Shepherd, and T. Le Chevalier Activity of gemcitabine in patients with non-small-cell lung cancer: a multicenter, extended phase II study Eur J Cancer A 32 1996 243 248
13. T. Le Chevalier, D. Brisgand, and J.Y. Douillard Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients J Clin Oncol 12 1994 360 367
14. World Health Organization The WHO handbook for reporting results of cancer treatment, vol. 48 1979 World Health Organization Geneva, Switzerland
15. R. Simon Optimal two-stage designs for phase II clinical trials Contr Clin Trials 10 1989 1 10
16. R. Lilenbaum, R. Cano, and M. Schwartz Gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: a phase II study Cancer 88 2000 557 562
17. E. Bajetta, S. Chiara Stani, and D. DeCandis Gemcitabine plus vinorelbine as first-line chemotherapy in advanced nonsmall cell lung carcinoma a phase II trial Cancer 89 2000 763 768
18. G. Frasci, V. Lorusso, and N. Panza Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer J Clin Oncol 18 2000 2529 2536
19. C. Gridelli, L. Frontini, and F. Perrone Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses. Gem-Vin investigators Br J Cancer 83 2000 707 714
20. G.D. Beretta, G. Michetti, and M.O. Belometti Gemcitabine plus vinorelbine in elderly or unfit patients with non-small-cell lung cancer Br J Cancer 83 2000 573 576
21. C. Gridelli, S. Cigolari, and C. Gallo Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small-cell lung cancer elderly patients: phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial Lung Cancer 31 2001 277 284
22. E. Esteban, J. Fra, and N. Corral Phase I/II study of gemcitabine plus vinorelbine in non-small cell lung cancer Invest New Drugs 20 2002 73 82
23. N. Katakami, T. Sugiura, and T. Nogami Combination chemotherapy of gemcitabine and vinorelbine for patients in stage IIIb-IV non-small cell lung cancer: a phase II study of the West Japan Thoracic Oncology Group (WJTOG) 9908 Lung Cancer 43 2004 93 100
24. R.C. Lilenbaum, C.S. Chen, and T. Chidiac Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer Ann Oncol 16 2005 97 101
25. O-P. Isokangas, A. Knuuttila, and M. Halme Phase II study of vinorelbine and gemcitabine for inoperable stage IIIB-IV non-small-cell lung cancer Ann Oncol 10 1999 1059 1063
26. J. Feliu, L. Lopez Gomez, and C. Madronal Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 or older or patients who cannot receive cisplatin. Oncopaz Cooperative Group Cancer 86 1999 1463 1469
27. Y-M. Chen, R-P. Perng, and K-Y. Yang A multicenter phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIb/IV) non-small cell lung cancer Chest 117 2000 1583 1589
28. F. Baron, J. Cueva, and B. Grana Gemcitabine plus vinorelbine for the treatment of advanced non-small cell lung cancer Eur J Cancer 37 2001 1381 1384
29. S. Palmeri, V. Leonardi, and V. Gebbia Gemcitabine plus vinorelbine in stage IIIb or IV non-small cell lung cancer (NSCLC): a multicentre phase II clinical trial Lung Cancer 34 2001 115 123
30. E. Laack, T. Mende, and J. Benk Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer: a phase II trial Eur J Cancer 37 2001 583 590
31. F.A. Greco, J.R. Gray, and D.S. Thompson Prospective randomized study of four novel chemotherapy regimens in patients with advanced non-small-cell lung carcinoma: a Minnie Pearl Cancer Research Network trial Cancer 95 2002 1279 1285
32. R.S. Herbst, F.R. Khuri, and C. Lu The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy Cancer 95 2002 340 353
33. Y-M. Chen, R-P. Perng, and M-C. Chen A phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIb/IV) non-small-cell lung cancer patients aged 80 or older Lung Cancer 40 2003 221 226
34. M.S. Aapro, C. Martin, and S. Hatty Gemcitabine, a safety review Anticancer Drugs 9 1998 191 201
35. C. Gridelli, F. Perrone, and C. Gallo Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial J Natl Cancer Inst 95 2003 362 372
36. G. Frasci, V. Lorusso, and N. Panza Gemcitabine plus vinorelbine yields better survival outcome than vinorelbine alone in elderly patients with advanced non-small cell lung cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase III trial Lung Cancer 34 Suppl 4 2001 S65 S69
37. P. Comella, G. Frasci, and P. Carnicelli Gemcitabine with either paclitaxel or vinorelbine vs. paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer Br J Cancer 91 2004 489 497
38. E. Laack, N. Dickgreber, and T. Müller Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group J Clin Oncol 22 2004 2348 2356
39. V. Georgoulias, E. Papadakis, and A. Alexopoulos Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial Lancet 357 2001 1478 1484
40. E.F. Smit, J.P. van Meerbeeck, and P. Lianes Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group - EORTC 08975 J Clin Oncol 21 2003 3909 3917
41. D.G. Pfister, D.H. Johnson, and C.G. Azzoli American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003 J Clin Oncol 22 2004 330 353